睿昂基因(688217.SH):預計2024年淨虧損1129.43萬元到1694.15萬元
格隆匯1月17日丨睿昂基因(688217.SH)公佈,1、經財務部門初步測算,公司預計2024年年度實現營業收入23,800萬元至24,500萬元,與上年同期(法定披露數據)相比,同比減少5.12%至7.83%。2、公司預計2024年年度實現歸屬於母公司所有者的淨利潤為-1,129.43萬元到-1,694.15萬元,與上年同期相比,將出現虧損。3、公司預計2024年年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為-1,479.70萬元至-2,044.41萬元。
1、報吿期內,公司一季度營業收入較去年同期上升12.84%;公司第二季度營業收入較去年同期基本持平;2024年三季度受突發事件影響,公司7-8月產品入院進度有所延遲,當季營業收入較去年同期下滑23.04%;2024年第四季度,公司營業收入較去年同期下滑幅度大幅縮小。上述原因導致公司2024年營業收入較上年度下降約1,321.13萬元至2,021.13萬元,同比減少5.12%至7.83%,營業收入下降導致毛利金額下降;2、報吿期內,公司匯豐西路新廠房及公租房於2023年3月、9月投入使用,導致折舊攤銷費用較上年度增加104.19萬元;本期因公司突發事件產生法律諮詢費用共計450.68萬元,而上年度同期無類似費用;3、報吿期內,受醫療行業不景氣影響,下游客户回款變慢,本期公司根據壞賬政策對應收賬款計提信用減值損失931.74萬元,較上年度增加380.10萬元;4、報吿期內,上海睿昂基因科技股份有限公司子公司思泰得生物及武漢百泰受到醫療行業以及公司戰略調整的影響,導致營業收入不及預期,本期計提商譽減值1,430.41萬元,較上年度增加681.01萬元
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.